|
1
|
PDQ Adult Treatment Editorial Board:
Non-small cell lung cancer treatment (PDQ®): Patient Version, . PDQ
cancer information summaries [Internet]. Nat Cancer Inst (US);
Bethesda: https://www.ncbi.nlm.nih.gov/books/NBK65917/April
13–2017
|
|
2
|
Pao W and Girard N: New driver mutations
in non-small-cell lung cancer. Lancet Oncol. 12:175–180. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Soria JC, Mok TS, Cappuzzo F and Jänne PA:
EGFR-mutated oncogene-addicted non-small cell lung cancer: Current
trends and future prospects. Cancer Treat Rev. 38:416–430. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Nguyen KS and Neal JW: First-line
treatment of EGFR-mutant non-small-cell lung cancer: The role of
erlotinib and other tyrosine kinase inhibitors. Biologics.
6:337–345. 2012.PubMed/NCBI
|
|
5
|
Pao W, Miller VA, Politi KA, Riely GJ,
Somwar R, Zakowski MF, Kris MG and Varmus H: Acquired resistance of
lung adenocarcinomas to gefitinib or erlotinib is associated with a
second mutation in the EGFR kinase domain. PLoS Med. 2:e732005.
View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Wu PF, Zhu YP, Yang CH, Wang YF and Wang
GH: The Mechanism and countermeasures on the secondary resistance
of Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor
(EGFR-TKI). Anti-Tumor Pharm. 5:42015.
|
|
7
|
Thiery JP, Acloque H, Huang RY and Nieto
MA: Epithelial-mesenchymal transitions in development and disease.
Cell. 139:871–890. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Robert G, Gaggioli C, Bailet O, Chavey C,
Abbe P, Aberdam E, Sabatié E, Cano A, de Herreros Garcia A,
Ballotti R and Tartare-Deckert S: SPARC represses E-cadherin and
induces mesenchymal transition during melanoma development. Cancer
Res. 66:7516–7523. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Voulgari A and Pintzas A:
Epithelial-mesenchymal transition in cancer metastasis: Mechanisms,
markers and strategies to overcome drug resistance in the clinic.
Biochim Biophys Acta. 1796:75–90. 2009.PubMed/NCBI
|
|
10
|
Neel DS and Bivona TG: Secrets of drug
resistance in NSCLC exposed by new molecular definition of EMT.
Clin Cancer Res. 19:3–5. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Uramoto H, Iwata T, Onitsuka T, Shimokawa
H, Hanagiri T and Oyama T: Epithelial-mesenchymal transition in
EGFR-TKI acquired resistant lung adenocarcinoma. Anticancer Res.
30:2513–2517. 2010.PubMed/NCBI
|
|
12
|
Tatnell PJ, Powell DJ, Hill J, Smith TS,
Tew DG and Kay J: Napsins: New human aspartic proteinases.
Distinction between two closely related genes. FEBS Lett.
441:43–48. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Chuman Y, Bergman A, Ueno T, Saito S,
Sakaguchi K, Alaiya AA, Franzén B, Bergman T, Arnott D, Auer G, et
al: Napsin A, a member of the aspartic protease family, is
abundantly expressed in normal lung and kidney tissue and is
expressed in lung adenocarcinomas. FEBS Lett. 462:129–134. 1999.
View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Schauer-Vukasinovic V, Bur D, Kling D,
Grüninger F and Giller T: Human napsin A: Expression,
immunochemical detection, and tissue localization. FEBS Lett.
462:135–139. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Hirano T, Auer G, Maeda M, Hagiwara Y,
Okada S, Ohira T, Okuzawa K, Fujioka K, Franzén B, Hibi N, et al:
Human tissue distribution of TA02, which is homologous with a new
type of aspartic proteinase, napsin A. Jpn J Cancer Res.
91:1015–1021. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Hirano T, Gong Y, Yoshida K, Kato Y,
Yashima K, Maeda M, Nakagawa A, Fujioka K, Ohira T, Ikeda N, et al:
Usefulness of TA02 (napsin A) to distinguish primary lung
adenocarcinoma from metastatic lung adenocarcinoma. Lung Cancer.
41:155–162. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Ueno T, Linder S and Elmberger G: Aspartic
proteinase napsin is a useful marker for diagnosis of primary lung
adenocarcinoma. Br J Cancer. 88:1229–1233. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Hirano T, Auer G, Maeda M, Hagiwara Y,
Okada S, Ohira T, Okuzawa K, Fujioka K, Franzén B, Hibi N, et al:
Human tissue distribution of TA02, which is homologous with a new
type of aspartic proteinase, napsin A. Jpn J Cancer Res.
91:1015–1021. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Ueno T, Elmberger G, Weaver TE, Toi M and
Linder S: The aspartic protease napsin A suppresses tumor growth
independent of its catalytic activity. Lab Invest. 88:256–263.
2008. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Meena AS, Sharma A, Kumari R, Mohammad N,
Singh SV and Bhat MK: Inherent and acquired resistance to
paclitaxel in hepatocellular carcinoma: Molecular events involved.
PLoS One. 8:e615242013. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Hauck CR, Hsia DA and Schlaepfer DD: The
focal adhesion kinase-a regulator of cell migration and invasion.
IUBMB Life. 53:115–119. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Xie B, Zhao J, Kitagawa M, Durbin J, Madri
JA, Guan JL and Fu XY: Focal adhesion kinase activates Stat1 in
integrin-mediated cell migration and adhesion. J Biol Chem.
276:19512–19523. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Bhowmick NA, Zent R, Ghiassi M, McDonnell
M and Moses HL: Integrin beta 1 signaling is necessary for
transforming growth factor-beta activation of p38MAPK and
epithelial plasticity. J Biol Chem. 276:46707–46713. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Zheng JX, Guan SH, Xu Q, Liu JZ and Song
P: Inhibition of epithelial-mesenchymal transition in A549 cell by
transfected Napsin A. Chin Med J (Engl). 125:2734–2740.
2012.PubMed/NCBI
|
|
25
|
Hauck CR, Sieg DJ, Hsia DA, Loftus JC,
Gaarde WA, Monia BP and Schlaepfer DD: Inhibition of focal adhesion
kinase expression or activity disrupts epidermal growth
factor-stimulated signaling promoting the migration of invasive
human carcinoma cells. Cancer Res. 61:7079–7090. 2001.PubMed/NCBI
|
|
26
|
Sieg DJ, Hauck CR, Ilic D, Klingbeil CK,
Schaefer E, Damsky CH and Schlaepfer DD: FAK integrates
growth-factor and integrin signals to promote cell migration. Nat
Cell Biol. 2:249–256. 2000. View
Article : Google Scholar : PubMed/NCBI
|
|
27
|
Sieg DJ, Hauck CR and Schlaepfer DD:
Required role of focal adhesion kinase (FAK) for
integrin-stimulated cell migration. J Cell Sci. 112:2677–2691.
1999.PubMed/NCBI
|
|
28
|
Parsons JT, Martin KH, Slack JK, Taylor JM
and Weed SA: Focal adhesion kinase: A regulator of focal adhesion
dynamics and cell movement. Oncogene. 19:5606–5613. 2000.
View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Ruoslahti E: RGD and other recognition
sequences for integrins. Annu Rev Cell Dev Biol. 12:697–715. 1996.
View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Juliano RL: Signal transduction by cell
adhesion receptors and the cytoskeleton: Functions of integrins,
cadherins, selectins, and immunoglobulin-superfamily members. Annu
Rev Pharmacol Toxicol. 42:283–323. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Hynes RO: Integrins: Bidirectional,
allosteric signaling machines. Cell. 110:673–687. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Li Y, Yang J, Dai C, Wu C and Liu Y: Role
for integrin-linked kinase in mediating tubular epithelial to
mesenchymal transition and renal interstitial fibrogenesis. J Clin
Invest. 112:503–516. 2003. View Article : Google Scholar : PubMed/NCBI
|
